CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
This study provides the first high-content proteomic atlas of intrathecal ICI therapy in LM, identifies intrathecal ICI therapy-specific immune remodeling in LM, and establishes a CSF-based predictive model with high accuracy. ADGRG1 represents a promising biomarker of treatment responsiveness and a potential mechanistic link between macrophage biology and LM progression.
Authors
- Yang Guozi
- Panpan Tai
- Xi Chen (ORCID: https://orcid.org/0000-0002-8523-3967)
- Zhenyu Pan
- Lishi Wang
- Yushan Huang
- Hang Lei
- Yuancheng Zhang
- Bin Li
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Beijing Chest Hospital (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Guangzhou Medical University (CN)
- Huizhou University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013588
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guangzhou Medical University
- Basic and Applied Basic Research Foundation of Guangdong Province